2-[(3R)-3-fluoropyrrolidin-1-yl]acetamide | 1187325-47-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(3R)-3-fluoropyrrolidin-1-yl]acetamide
• CAS: 1187325-47-8
• 化学式: C₆H₁₁FN₂O
• 分子量: 146.165
• InChiKey: FAJZDEJJEYJGJG-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN
  申请人：Attardo Giorgio

  公开号：US20110105488A1

  公开（公告）日：2011-05-05

  The present application relates to pyrrolidine, piperidine, and other nitrogen-containing heterocyclic derivatives and the use of these compounds for treating and preventing pam or inflammation. The analgesic compounds demonstrate efficacy in the treatment of neuropathic pain resulting from a variety of conditions such as diabetic neuropathy, HIV infections, and post-herpetic neuralgia.

  本申请涉及吡咯烷，哌啶和其他含氮杂环衍生物及其用于治疗和预防疼痛或炎症的用途。这些镇痛化合物在治疗由各种情况引起的神经病理性疼痛方面表现出有效性，如糖尿病神经病变，HIV感染和带状疱疹后神经痛。
• Tetracycline Compounds
  申请人：Deng Yonghong

  公开号：US20120208788A1

  公开（公告）日：2012-08-16

  The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

  本发明涉及一种由结构式（1）表示的化合物或其药学上可接受的盐。结构式（I）的变量在此定义。本发明还描述了包含结构式（I）化合物的药物组合物及其治疗用途。
• Isoquinolin-3-yl carboxamides and preparation and use thereof
  申请人：BioSplice Therapeutics, Inc.

  公开号：US11174244B2

  公开（公告）日：2021-11-16

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  本发明公开了用于治疗各种疾病和病理的异喹啉化合物。更具体地说，本公开涉及异喹啉化合物或其类似物在治疗以 Wnt 通路信号激活为特征的疾病（如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病、炎症、自身免疫性疾病和骨关节炎）、调节由 Wnt 通路信号介导的细胞事件以及与 DYRK1A 过度表达相关的神经系统状况/紊乱/疾病中的用途。
• TETRACYCLINE COMPOUNDS
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：EP2470500B1

  公开（公告）日：2017-10-04
• ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20200339536A1

  公开（公告）日：2020-10-29

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.